Donor leucocyte infusions (DLI) are an effective but not innocuous treatment option for patients with CML relapsing after allogeneic BMT. 1 Despite dramatic antileukemic potential they have a significant toxicity with GVHD and aplasia as the main causes of a mortality rate that may approach 20%. 2 The myelosuppression that may follow DLI is presumably due to destruction of the patient leukemic cells and the probability of its occurrence seems to be inversely correlated with the amount of residual donor hematopoiesis. Some patients may have persistent marrow aplasia and require further infusion of donor stem cells in order to achieve full hematopoietic reconstitution. The proportion of donor cells sufficient for hematopoietic recovery is not known, but patients with less than 5% residual donor cells were noted to experience transient severe pancytopenia. 3 We hypothesized that the administration of donor G-CSF-mobilized PBPC might alleviate the problem of pancytopenia, whilst retaining the GVL effect. Between September 1994 and January 1997, we studied five patients with CML in hematologic relapse after allogeneic BMT (Table 1 ). All had been transplanted with unmanipulated marrow from an HLA-identical sibling between 6 and 120 months before relapse was detected. In order to obtain PBPC for salvage therapy, donors were given G-CSF s.c. at a dose of 10 g/kg daily for 4 or 5 days and cells were obtained by leukapheresis in one or two sessions using a COBE Spectra cell separator (Cobe, Lakewood, CO, USA). The collected cells, containing a median of 3.37 × 10 6 /l CD34+ve and 20.9 × 10 7 /l CD3+ve cells, were infused immediately and no post-transfusion GVHD prophylaxis was given.
All patients were mixed chimeras at the time of cell infusion as assessed on peripheral blood by PCR analysis of variable number of tandem repeats or FISH for the X and Y chromosomes on bone marrow cells. Two patients a Defined as neutrophils Ͻ0.5 × 10 9 /l and/or platelets Ͻ20 × 10 9 /l. CP = chronic phase; AP = accelerated phase; AW = alive and well; MR = molecular remission defined as no BCR-ABL mRNA transcripts on two consecutive PCR assays; FU = follow-up.
with less than 10% residual donor cells experienced moderate myelosuppression of short duration (less than 3 days) and the other three had no significant myelotoxicity. Prophylatic antibiotics or G-CSF were not given and no patient needed admission to hospital. GVHD was diagnosed in three patients and controlled without difficulty, although one patient with liver involvement (peak bilirubin value 6.3 mg/dl) needed 6 months therapy with CsA and prednisone for complete resolution of the disease. This patient was already in cytogenetic remission before immunosuppression was started and achieved molecular remission while still on CsA.
Molecular remission was achieved in all patients between days 80 and 347 after PBPC infusion, as assessed by nested PCR for BCR-ABL mRNA. It is interesting to note that patient 5 who had accelerated disease with marked leukocytosis, hepatosplenomegaly and unremitting fever did not develop GVHD and was the first to achieve a complete remission being in molecular remission 80 days after PBPC infusion. At a median follow-up of 34 months, all patients are alive and well in sustained molecular remission.
Our data and that of others 4,5 suggest that the pre-emptive use of PBPC instead of donor leukocytes may alleviate the pancytopenia that follows salvage immunotherapy and improve its results. This approach may be particularly useful in patients found to have less than 10% residual donor cells who might otherwise experience a prolonged period of profound myelosuppression. 
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How should corticosteroids be used in the treatment of acute GVHD?
Acute GVHD is the most important complication of allogeneic BMT, and its successful management is crucial to the outcome of treatment. First-line treatment of acute GVHD is usually corticosteroids. In a recent survey among EBMT centres, all of the 86 centres which reported their treatment practices used corticosteroids, usually methylprednisolone (MP), as first-line treatment. 1 However, the treatment is given variably. According to the survey, there were differences in the grade of GVHD which indicated treatment (any apparent acute GVHD vs grade II or more) as well as in the dosage. The most commonly used initial dose was 2 mg/kg/day intravenously, but a considerable proportion of the centres gave 5 mg/kg/day or more, and the initial dosage ranged between 1 and 20 mg/kg/day. At many centres the dose was dependent on the severity of GVHD.
It is not known whether an aggressive or more restrained use of corticosteroids is preferable. Acute GVHD might be controlled more effectively by giving corticosteroids early and in high doses. However, the untoward effects of corticosteroids are well-known; the possibility of increasing the risk of infections in these immunosuppressed patients must particularly be taken into account. On the other hand, GVHD, especially chronic GVHD, is known to be immunosuppressive, and effectively stopping the GVHD process might be advantageous for the recovery of the immunological system. Van Lint and co-workers 2 have recently published results of a randomized study indicating that treatment of acute GVHD with an initial dose of 10 mg/kg/day was not more effective than with a dose of 2 mg/kg/day. We have utilized the results of the EBMT survey and the EBMT registry database to discover the influence of intensity of corticosteroid treatment on the outcome of patients with acute GVHD.
Among the centres which participated in the survey, two clearly different groups were identified according to the intensity of the use of corticosteroids. Twelve centres treated only acute GVHD grade II or more and initially gave 2 mg/kg/day methylprednisolone irrespective of the severity of GVHD. Six centres treated acute GVHD at the first clinical signs likely to be caused by GVHD and gave 10 mg/kg/day or more. The outcome of all patients with chronic myeloid leukaemia treated at the two groups of centres was then recorded using the EBMT database. All these patients had been given GVHD prophylaxis with cyclosporin and a short course of methotrexate. There were 250 patients altogether treated at the centres using the less intense approach and 125 patients at the centres using the more intense policy. Figure 1 shows the survival of these two patient groups. The survival of patients treated at the centres giving less intensive corticosteroid treatment for acute GVHD was highly significantly (P = 0.00006, log rank test) better than that of patients treated at the centres giving more intense corticosteroid treatment. There was a non-significant trend towards a higher relapse rate in the intensively treated group (Figure 2) . Table 1 shows the principal causes of death. There were significantly more deaths due to infections in the more intensely treated group and also significantly more deaths from graft failure.
The present results indicate that intense treatment of acute GVHD with high doses of corticosteroids does not give better results than a more conventional approach with 
